Abcam (LON:ABC) Rating Reiterated by Peel Hunt
Other equities analysts have also issued reports about the company. JPMorgan Chase & Co. reiterated a neutral rating and issued a GBX 864 ($12.13) target price on shares of Abcam in a research note on Tuesday, September 12th. Numis Securities upped their price target on Abcam from GBX 1,116 ($15.67) to GBX 1,200 ($16.85) and gave the stock an add rating in a research note on Tuesday, September 12th. Berenberg Bank restated a buy rating and set a GBX 1,100 ($15.45) price target on shares of Abcam in a research note on Monday, September 11th. Finally, Panmure Gordon restated a sell rating on shares of Abcam in a research note on Monday, September 11th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company’s stock. The company has an average rating of Hold and an average target price of GBX 1,009.33 ($14.17).
Abcam (LON ABC) traded up GBX 15 ($0.21) during midday trading on Friday, hitting GBX 1,214 ($17.05). The stock had a trading volume of 280,986 shares, compared to its average volume of 264,290. The firm has a market capitalization of $2,490.00 and a PE ratio of 5,780.95. Abcam has a 12 month low of GBX 9.73 ($0.14) and a 12 month high of GBX 1,220 ($17.13).
Abcam plc is a global life sciences company. As a developer of reagents and tools, the Company’s purpose is to serve life science researchers globally. Providing the research and clinical communities with tools and scientific support, the Company offers validated biological binders and assays to address important targets in critical biological pathways.
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.